Bärtsch, M., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., . . . Goldschmidt, H. (2021). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood cancer journal, 11(1), . https://doi.org/10.1038/s41408-020-00390-3
Chicago-Zitierstil (17. Ausg.)Bärtsch, Marc-Andrea, et al. "Lenalidomide Versus Bortezomib Maintenance After Frontline Autologous Stem Cell Transplantation for Multiple Myeloma." Blood Cancer Journal 11, no. 1 (2021). https://doi.org/10.1038/s41408-020-00390-3.
MLA-Zitierstil (9. Ausg.)Bärtsch, Marc-Andrea, et al. "Lenalidomide Versus Bortezomib Maintenance After Frontline Autologous Stem Cell Transplantation for Multiple Myeloma." Blood Cancer Journal, vol. 11, no. 1, 2021, https://doi.org/10.1038/s41408-020-00390-3.